Restenosis rates following bifurcation stenting with sirolimus-eluting stents for de novo narrowings

The percutaneous treatment of coronary bifurcation stenoses is hampered by an increased rate of subsequent restenosis. The present study reports on the outcomes of a consecutive series of 58 patients with 65 de novo bifurcation stenoses treated with sirolimus-eluting stent implantation in both the m...

Full description

Saved in:
Bibliographic Details
Published in:The American journal of cardiology 2004-07, Vol.94 (1), p.115-118
Main Authors: Tanabe, Kengo, Hoye, Angela, Lemos, Pedro A, Aoki, Jiro, Arampatzis, Chourmouzios A, Saia, Francesco, Lee, Chi-hang, Degertekin, Muzzafer, Hofma, Sjoerd H, Sianos, Georgios, McFadden, Eugene, Smits, Pieter C, van der Giessen, Willem J, de Feyter, Pim, van Domburg, Ron T, Serruys, Patrick W
Format: Article
Language:English
Subjects:
Angioplasty, Balloon, Coronary
Biological and medical sciences
Cardiology
Cardiology. Vascular system
Cardiovascular disease
Coronary Angiography
Coronary Artery Disease - diagnostic imaging
Coronary Artery Disease - drug therapy
Coronary Artery Disease - pathology
Coronary Artery Disease - therapy
Coronary Restenosis - diagnostic imaging
Coronary Restenosis - mortality
Coronary Restenosis - pathology
Female
Florida
Humans
Immunosuppressive Agents - administration & dosage
Incidence
Male
Medical sciences
Middle Aged
Registries
Sirolimus - administration & dosage
Stents
Treatment Outcome
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:The percutaneous treatment of coronary bifurcation stenoses is hampered by an increased rate of subsequent restenosis. The present study reports on the outcomes of a consecutive series of 58 patients with 65 de novo bifurcation stenoses treated with sirolimus-eluting stent implantation in both the main vessel and side branch. At 6 months, the incidence of major adverse cardiac events was 10.3% (1 death and 5 target lesion revascularizations) with no episodes of acute myocardial infarction or stent thrombosis.
ISSN:0002-9149
1879-1913
DOI:10.1016/j.amjcard.2004.03.040